{"schema_version":"secwatch.filing_event.v1","accession":"0000816956-25-000054","form_type":"8-K","ticker":"CNMD","cik":"0000816956","company_name":"CONMED Corp","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.254484+00:00","generated_at":"2026-05-17T00:28:28.952363+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CONMED Q3 revenue up 6.7% to $338M; adjusted EPS $1.08; suspends dividend, authorizes $150M buyback","bullets":["Diluted GAAP EPS $0.09 vs $1.57 YoY due to $19.7M product rationalization and $9.2M consulting costs.","Adjusted diluted EPS $1.08 vs $1.05 YoY; full-year adjusted EPS guidance raised to $4.48-$4.53.","Full-year revenue guidance narrowed to $1.365B-$1.372B; tariffs expected to reduce Q4 EPS by ~$0.07.","Board authorized $150M share repurchase program; quarterly cash dividend suspended; at least $25M annual buybacks from 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000816956-25-000054","json":"https://secwatch.observer/filing/0000816956-25-000054.json","markdown":"https://secwatch.observer/filing/0000816956-25-000054.md","text":"https://secwatch.observer/filing/0000816956-25-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/816956/000081695625000054/0000816956-25-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/816956/000081695625000054/cnmd-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:28:28.952363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}